Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Telaprevir in a patient with chronic hepatitis C and cryoglobulinemic glomerulonephritis.

De Nicola S, Aghemo A, Campise MR, D'Ambrosio R, Rumi MG, Messa P, Colombo M.

Antivir Ther. 2014;19(5):527-31. doi: 10.3851/IMP2684. Epub 2013 Sep 6.

PMID:
24009104
2.

Interferon-alpha in combination with ribavirin as initial treatment for hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis.

Garini G, Allegri L, Carnevali L, Catellani W, Manganelli P, Buzio C.

Am J Kidney Dis. 2001 Dec;38(6):E35.

PMID:
11728995
3.

Hepatitis C virus-related cryoglobulinemia and glomerulonephritis: pathogenesis and therapeutic strategies.

Garini G, Allegri L, Vaglio A, Buzio C.

Ann Ital Med Int. 2005 Apr-Jun;20(2):71-80. Review.

PMID:
16052839
4.

HCV-related cryoglobulinemic glomerulonephritis: implications of antiviral and immunosuppressive therapies.

Garini G, Allegri L, Lannuzzella F, Vaglio A, Buzio C.

Acta Biomed. 2007;78(1):51-9.

PMID:
17687818
5.

[Membranoproliferative glomerulonephritis in patients with cryoglobulinemia complicating hepatitis C virus: report of 11 cases].

Ben Fatma L, Ben Hamida F, Aoudia R, Goucha R, Kaaroud H, Béji S, Barbouch S, Hedri H, Abderrahim E, Elyounsi F, Ben Abdallah T, Ben Moussa F, Kheder A.

Tunis Med. 2007 Mar;85(3):220-4. French.

PMID:
17668578
6.

Patterns of viral load decline with telaprevir-based therapy in patients with genotype 1 chronic HCV infection.

Picchio G, De Meyer S, Dierynck I, Ghys A, Gritz L, Kieffer TL, Bartels DJ, Witek J, Bengtsson L, Luo D, Kauffman RS, Adda N, Sarrazin C.

J Clin Virol. 2014 Mar;59(3):148-55. doi: 10.1016/j.jcv.2013.12.011. Epub 2014 Jan 6.

PMID:
24462470
7.

Treatment of hepatitis C-related kidney disease.

Fabrizi F, Martin P, Cacoub P, Messa P, Donato FM.

Expert Opin Pharmacother. 2015;16(12):1815-27. doi: 10.1517/14656566.2015.1066333. Epub 2015 Jul 10. Review.

PMID:
26161511
8.

[Steroids, interferon-alpha and ribavirin treatment of cryoglobulinemic glomerulonephritis concurrent with HCV infection].

Guarnieri A, Marazzi F, Giorgi MP, Canepari G, Pino C, Moggia E, Manca A, Ghezzi PM.

G Ital Nefrol. 2002 Jan-Feb;19(1):79-81. Italian.

PMID:
12165950
9.

Triple therapy with boceprevir or telaprevir for prior HCV non-responders.

Asselah T.

Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):455-62. doi: 10.1016/j.bpg.2012.09.003.

PMID:
23199504
10.

Future perspectives: towards interferon-free regimens for HCV.

Gane E.

Antivir Ther. 2012;17(6 Pt B):1201-10. doi: 10.3851/IMP2431. Epub 2012 Oct 5. Review.

PMID:
23186654
11.

Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: is it feasible?

Dumortier J, Guillaud O, Gagnieu MC, Janbon B, Juillard L, Morelon E, Leroy V.

J Clin Virol. 2013 Feb;56(2):146-9. doi: 10.1016/j.jcv.2012.10.009. Epub 2012 Nov 11.

PMID:
23149155
12.

Therapy of hepatitis C virus-associated glomerulonephritis: current approaches.

Fabrizi F, Lunghi G, Messa P, Martin P.

J Nephrol. 2008 Nov-Dec;21(6):813-25. Review.

PMID:
19034865
13.

Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score.

Virlogeux V, Pradat P, Bailly F, Funingana G, Gonçalves F, Maynard M, Hartig-Lavie K, Amiri M, Zoulim F.

J Viral Hepat. 2014;21(9):e98-e107. doi: 10.1111/jvh.12237. Epub 2014 Feb 25.

PMID:
24612466
14.

The effect of combination therapy with interferon and cryofiltration on mesangial proliferative glomerulonephritis originating from mixed cryoglobulinemia in chronic hepatitis C virus infection.

Kiyomoto H, Hitomi H, Hosotani Y, Hashimoto M, Uchida K, Kurokouchi K, Nagai M, Takahashi N, Fukunaga M, Mizushige K, Matsuo H, Yuasa S.

Ther Apher. 1999 Nov;3(4):329-33.

PMID:
10608730
15.

A case of rapid amelioration of hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis treated by interferon-free directly acting antivirals for HCV in the absence of immunosuppressant.

Obata F, Murakami T, Miyagi J, Ueda S, Inagaki T, Minato M, Ono H, Nishimura K, Shibata E, Tamaki M, Yoshimoto S, Kishi F, Kishi S, Matsuura M, Nagai K, Abe H, Doi T.

CEN Case Rep. 2017 May;6(1):55-60. doi: 10.1007/s13730-016-0244-z. Epub 2016 Nov 21.

16.

Influence of low-density lipoprotein cholesterol on virological response to telaprevir-based triple therapy for chronic HCV genotype 1b infection.

Ogawa E, Furusyo N, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Nakamuta M, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group..

Antiviral Res. 2014 Apr;104:102-9. doi: 10.1016/j.antiviral.2014.01.004. Epub 2014 Jan 23.

PMID:
24462955
17.

Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience.

Faisal N, Yoshida EM, Bilodeau M, Wong P, Ma M, Burak KW, Al-Judaibi B, Renner EL, Lilly LB.

Ann Hepatol. 2014 Sep-Oct;13(5):525-32.

18.

A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.

Chen EY, Sclair SN, Czul F, Apica B, Dubin P, Martin P, Lee WM.

Clin Gastroenterol Hepatol. 2013 Aug;11(8):1014-20.e1-2. doi: 10.1016/j.cgh.2013.03.032. Epub 2013 Apr 16.

PMID:
23602817
19.

Future of hepatitis C therapy: development of direct-acting antivirals.

Dore GJ, Matthews GV, Rockstroh J.

Curr Opin HIV AIDS. 2011 Nov;6(6):508-13. doi: 10.1097/COH.0b013e32834b87f8. Review.

PMID:
21897228
20.

Cryoglobulinemia-related vasculitis during effective anti-HCV treatment with PEG-interferon alfa-2b.

De Blasi T, Aguilar Marucco D, Cariti G, Maiello A, De Rosa FG, Di Perri G.

Infection. 2008 Jun;36(3):285-7. Epub 2007 Oct 25.

PMID:
17962905

Supplemental Content

Support Center